NASDAQ$EVLO
Evelo Biosciences Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported financial results and business highlights for the first quarter 2021.
Evelo Biosciences reported its Q1 2021 financial results, highlighting positive data from the Phase 1b clinical trial of EDP1815 for atopic dermatitis and a strategic collaboration with Abdul Latif Jameel Health. The company also strengthened its leadership team with new appointments.
- Presented positive data from Phase 1b clinical trial of EDP1815 for atopic dermatitis at ISAD Meeting.
- Strengthened leadership team with the appointments of Luca Scavo as CFO and Julie H. McHugh to Board of Directors.
- Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets.
- Multiple clinical data readouts expected over next 18 months.
Headline financials
Revenue & EPS history
Evelo · Revenue · Quarterly
$0
Forward guidance
Evelo Biosciences anticipates multiple clinical data readouts across its inflammatory disease portfolio in the next 18 months. Key milestones include data from the Phase 2b dose-ranging trial of EDP1815 in psoriasis anticipated in Q3 2021, and interim data from the Phase 1b trial of EDP1867 in atopic dermatitis expected in Q4 2021.
Tailwinds
- Data from Phase 1b cohorts with tablets and capsules for Psoriasis anticipated in 3Q 2021
- Full data from Phase 2b dose-ranging trial for Psoriasis anticipated in 3Q 2021
- Subject to regulatory approval, initiation of Phase 2 trial in Atopic Dermatitis in 3Q 2021
- Interim data from Phase 1b trial for Atopic Dermatitis expected in 4Q 2021
- Initiation of clinical development for Inflammation in 2022
Headwinds
- Given the increase in vaccination rates, and lower number of patients hospitalized with COVID-19 at clinical trial sites, COVID-19 trials will continue longer than originally planned.
- The Company is unsure when it will be able to report data for COVID-19 trials
- The Company will no longer be issuing guidance related to COVID-19 trials.
- Potential delays in reporting data from clinical trials
- Uncertainties regarding the impact of COVID-19 on clinical trial timelines
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+1.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-9.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+32.3%
Q2 2023
Best reaction
-20.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +0.0% | +0.0% | -9.8% | |
| Q3 2023 | -7.6% | +4.5% | +3.8% | |
| Q2 2023 | +32.3% | -30.5% | -41.0% | |
| Q1 2023 | +2.9% | +10.2% | -28.8% | |
| Q4 2022 | -17.8% | -27.0% | -46.9% | |
| Q3 2022 | +3.3% | -3.3% | -8.5% | |
| Q2 2022 | -7.1% | -10.5% | -25.4% | |
| Q1 2022 | -20.3% | -14.5% | -2.4% | |
| Q4 2021 | +29.4% | +13.5% | -26.3% | |
| Q3 2021 | +10.2% | +27.0% | +6.0% | |
| Q2 2021 | -0.9% | +5.0% | +20.7% | |
| Q1 2021 | +8.8% | -14.4% | +11.0% | |
| Q4 2020 | +14.5% | +21.2% | +1.6% | |
| Q3 2020 | -12.9% | -5.9% | +14.0% | |
| Q2 2020 | -1.6% | -0.5% | +15.2% | |
| Q1 2020 | -5.7% | -14.0% | -20.9% | |
| Q4 2019 | +1.8% | +12.2% | -28.4% | |
| Q3 2019 | -3.3% | -6.1% | -35.9% | |
| Q2 2019 | +3.9% | -2.2% | +7.0% | |
| Q1 2019 | +0.8% | -1.5% | -11.8% | |
| Q4 2018 | +1.3% | +3.0% | -6.9% | |
| Q3 2018 | +0.2% | +3.4% | +3.7% | |
| Q2 2018 | -3.4% | -5.9% | +2.6% | |
| Q1 2018 | +1.8% | +2.2% | -24.8% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro